Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055
Alnylam Pharmaceuticals $661.25 million convertible senior notes offering
The 0% convertible notes are due 2028
Maze Therapeutics $150 million private placement
The PIPE included common stock and pre-funded warrants
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
Bruker mandatory convertible preferred stock offering
The preferred stock will be listed on Nasdaq
UST sale of HealthProof to Bain
We advised UST on the transaction
Precigen $125 million financing
We advised Precigen on the loan agreement
Ascletis HK$861.98 million placement of shares and top-up subscription
We advised the placing agent on the placement and the top-up subscription
Cardinal Health $1 billion notes offering
The investment-grade notes are due 2030 and 2035